Zynex Announces 2010 Year End Results

LITTLETON, Colo.--()--Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces a record number of orders and billed patients during 2010, which resulted in $24,085,000 of net revenue for 2010 versus $18,681,000 for 2009. Thomas Sandgaard, CEO, stated, “We are pleased with the consistent revenue growth we have been able to generate over the past several years.”

The Company reported a gross profit of $18,883,000 and SG&A expenses of $17,322,000 for 2010, as compared to a gross profit of $14,888,000 and SG&A expenses of $11,074,000 for 2009. During 2010, the Company made specific investments in its infrastructure to expand its domestic and international sales force, improve its billing and reimbursement department and relocate its headquarters to accommodate the significant increase in orders generated by the growing Zynex sales organization. The Company believes that, although these investments increased the 2010 SG&A expenses, they were necessary to yield long-term net revenue and net income growth and to continue to increase the Company’s cash collections. The Company also went through a CFO change in 2010, in which $200,000 of additional transition-related expense was incurred. The Company generated 2010 income from operations of $1,561,000, income before income taxes of $1,335,000 and net income of $350,000, versus income from operations of $3,814,000, income before income taxes of $3,823,000 and net income of $2,382,000 for 2009. The Company’s income tax expense for 2010 reflects a 74% effective tax rate due in part to assessed income tax penalties and interest. The Company is working with the respective taxing authorities to mitigate and abate these penalties and interest and hopes to avoid payment of the full amount of these penalties. The Company does not expect to incur tax penalties and interest at these amounts in future periods.

The Company’s continued focus on strengthening its balance sheet resulted in strong cash collections from customers, which resulted in a cash position of $602,000 as of December 31, 2010 and a revolving line of credit balance of $1,270,000.

Thomas Sandgaard, CEO stated: “2010 was a transformative year for us. The investments made in our sales team has paid off; as we have expanded our geographic reach and have increased the number of orders we are receiving on a monthly basis (as exhibited by our 29% increase in net revenue for 2010). Because of the demand for our products, we had to incur necessary expenses in our infrastructure to continue growth at our historical rates. Our primary expenditures were to sales and marketing and reimbursement and billing. We expect investing in these departments will result in continued sales growth and increased cash collections and will provide us with a long-term infrastructure to support increased sales. We also outgrew our primary operating facility/headquarters and relocated to a larger facility early in 2010. We believe investing in these SG&A expenses in 2010 should result in a revenue growth rate higher than that of our SG&A in future periods. I am pleased that, even with these necessary investments we made during 2010, our gross margins remained strong and we generated income from operations of $1,561,000, income before income taxes of $1,335,000 and net income of $350,000.”

Mr. Sandgaard continued: “Looking ahead, in addition to expanding our geographic reach for our Zynex Medical, electrotherapy subsidiary, we intend to focus our attention on two new very large markets, neurodiagnosis and cardiac monitoring, through our new subsidiaries Zynex NeuroDiagnostics and Zynex Monitoring Solutions. We have already begun executing our business plan for these subsidiaries and expect to see some results in 2011. We believe the combination of our core electrotherapy business (Zynex Medical), with the potential of our new subsidiaries (Zynex NeuroDiagnostics and Zynex Monitoring Solutions) should provide a significant platform for future revenue growth.”


The Company anticipates net revenues of between $30 million and $32 million for 2011 and net income per diluted share of between $0.08 and $0.11 for 2011.

Conference Call and Webcast Information:

Zynex, Inc. will host an earnings conference call and webcast at 9:00 a.m. MST (11:00 a.m. EST) today to discuss its 2010 year end results. Please note questions can only be submitted via the webcast user interface. Parties without access to the internet may join the presentation in listen only mode by dialing the toll free number provided below.

Webcast Information- http://www.visualwebcaster.com/event.asp?id=77408

Conference Call Information- 888-452-4024, passcode ZYNEX

Highlights from the year ended 2010 condensed consolidated financial statements:

(unaudited, amounts in thousands, except per share amounts)

      Year Ended
December 31,
2010         2009  
Net revenue $ 24,085 $ 18,681
Gross profit 18,883 14,888
Income from operations 1,561 3,814
Income before income taxes 1,335 3,823
Net income 350 2,382
Adjusted EBITDA (1) 3,519 4,595
Net income per share - diluted $ 0.01 $ 0.08
Weighted average number of common shares outstanding - diluted 30,704,737 30,374,360
Cash $ 602 $ 863
Total stockholders’ equity $ 8,182 $ 7,486



Reconciliation of unaudited U.S. Generally Accepted Accounting Principles (GAAP) Net income to Adjusted Earnings Before Interest Taxes Depreciation Amortization (EBITDA)

Year Ended
December 31,
  2010 2009  
Net income


350 $ 2,382
Interest and loss on extinguishment of debt 210 161


Depreciation and amortization 845 738
Non-cash deferred rent 1,129 44
Gain on value of derivative liability - (171 )
Adjusted EBITDA


3,519 $ 4,595  

About Zynex

Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex has also announced the development of two new business units, Zynex Monitoring Solutions and Zynex NeuroDiagnostic.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2009.




  December 31,     December 31,
2010 2009
Current Assets:
Cash $ 602 $ 863
Accounts receivable, net 7,309 5,039
Inventory 3,641 2,140
Prepaid expenses 145 139
Deferred tax asset 794 864
Other current assets   41   77
Total current assets 12,532 9,122
Property and equipment, net 2,906 2,612
Deposits 174 166
Deferred financing fees, net   89   30
$ 15,701 $ 11,930
Current Liabilities:
Line of credit $ 1,270 $ -
Current portion of capital lease obligations 93 95
Accounts payable 1,313 1,127
Income taxes payable 1,103 905
Accrued payroll and payroll taxes 572 426
Deferred rent liability 221 -
Other accrued liabilities   980   788
Total current liabilities 5,552 3,341
Capital lease obligations, less current portion 327 20
Deferred rent liability 1,452 544
Deferred tax liability   188   539
Total liabilities   7,519   4,444
Stockholders’ Equity:
Preferred stock; $.001 par value, 10,000,000 shares authorized,
no shares issued or outstanding - -
Common stock, $.001 par value, 100,000,000 shares authorized,
30,604,167 (2010) and 30,497,318 (2009) shares issued and outstanding 31 30
Paid-in capital 4,702 4,357
Retained earnings   3,449   3,099
Total stockholders’ equity   8,182   7,486
$ 15,701 $ 11,930





  2010       2009  
Net revenue:
Rental $ 8,533 $ 10,534
Sales   15,552     8,147  
  24,085     18,681  
Cost of revenue:
Rental 802 1,564
Sales   4,400     2,229  
  5,202     3,793  
Gross profit 18,883 14,888
Selling, general and administrative expense   17,322     11,074  
Income from operations   1,561     3,814  
Other income (expense):
Interest income 5 4
Interest expense and loss on extinguishment of debt (215 ) (165 )
Other expense (16 ) (1 )
Gain on value of derivative liability   -     171  
  (226 )   9  
Income before income taxes 1,335 3,823
Income tax expense   985     1,441  
Net income $ 350   $ 2,382  
Net income per share:
Basic $ 0.01   $ 0.08  
Diluted $ 0.01   $ 0.08  
Weighted average number of common
shares outstanding:
Basic   30,546,070     30,122,486  
Diluted   30,704,737     30,374,360  





  2010       2009  
Cash flows from operating activities:
Net income $ 350 $ 2,382
Adjustments to reconcile net income to net cash (used in) provided by
operating activities:
Depreciation expense 774 677
Provision for losses in accounts receivable (uncollectibility) 317 149
Amortization of deferred consulting and financing fees 71 61
Gain on value of derivative liability - (171 )
Issuance of stock for consulting services 79 188
Provision for obsolete inventory 23 267
Deferred rent expense 1,129 44
Loss on disposal of equipment 18 -
Employee stock based compensation expense 267 169
Deferred tax benefit (281 ) (105 )
Changes in operating assets and liabilities:
Accounts receivable (2,586 ) 427
Inventory (1,559 ) (91 )
Prepaid expenses (6 ) (66 )
Other current assets 17 (17 )
Accounts payable 186 89
Accrued liabilities 338 (590 )
Income taxes payable   198     235  
Net cash (used in) provided by operating activities   (665 )   3,648  
Cash flows from investing activities:
Proceeds received in lease termination 108 -
Deposits - 11
Purchases of equipment   (672 )   (955 )
Net cash used in investing activities   (564 )   (944 )
Cash flows from financing activities:
Decrease in bank overdraft - (113 )
Net borrowings from (payments on) line of credit 1,270 (1,781 )
Deferred financing fees (120 ) (30 )
Payments on notes payable and capital lease obligations (182 ) (37 )
Repayments of loans from stockholder - (25 )
Issuance of common stock   -     145  
Net cash provided by (used in) financing activities   968     (1,841 )
Net (decrease) increase in cash (261 ) 863
Cash at the beginning of the period   863     -  
Cash at the end of the period $ 602   $ 863  
Supplemental cash flow information:
Interest paid $ 112   $ 103  
Income taxes paid (including interest and penalties) $ 1,068   $ 1,311  
Supplemental disclosure of non-cash investing and financing activities:
Equipment acquired through capital lease $ 441   $ -  
Increase in deposit and deferred rent $ -   $ 156  
Increase in leasehold improvements and deferred rent $ -   $ 344  


Zynex, Inc.
Anthony Scalese, CFO


Zynex, Inc.
Anthony Scalese, CFO